Table of Contents

• 1. Introduction
• 2. The Two Avenues for Public Funding of Pharmaceutical and Other Biomedical R&D
• 3. The Story of Drug-Eluting Coronary Stents
• 4. The Incentives Issue
• 5. The Circumstances Affecting Incentives for the Development of Drug-Eluting Stents
• 6. A Proposal for Government Royalties for Biomedical Products Developed with Substantial Public Funding for R&D
• 7. Conclusion
• Acknowledgements
• Appendices
• A. Incomplete Pass Through of the Royalty to Price Given Market Power
• About the Authors
• References